← Back to screener

Larimar Therapeutics, Inc. LRMR

Rank #2209 · Nasdaq · $0.3B market cap
⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
29.2
P/E
-3.2
P/B
3.14
ROE
-98.6%
Op. Margin
–%
Debt Ratio
35%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -3.2x, P/B 3.14x. Ranks in the top 72% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -98.6%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 35%. Ranks in the top 19% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014$0.0B$-0.0B$-0.0B$-0.0B–-7
2015$0.0B$-0.0B$-0.0B$-0.1B–-24
2016$0.0B$-0.0B$-0.0B$-0.1B–-29
2017$0.0B$-0.1B$-0.1B$0.1B–9
2018$0.0B$-0.1B$-0.1B$0.2B–16
2019$0.0B$-0.1B$-0.1B$0.1B–23
2020–$-0.0B$-0.0B$0.0B–202
2021–$-0.0B$-0.0B$-0.0B–-2161
2022–$-0.1B$-0.1B$0.1B–16
2023–$-0.0B$-0.0B$0.1B–24
2024–$-0.0B$-0.0B$0.1B–13
2025–$-0.1B$-0.1B$0.1B–35

← See the full screener